Stockscreener 앱 받기
1.04
1.96%
0.02
전일 마감가:
$1.02
열려 있는:
$1.02
하루 거래량:
129.50K
Relative Volume:
0.69
시가총액:
$16.62M
수익:
-
순이익/손실:
$-43.10M
주가수익비율:
-0.1675
EPS:
-6.2098
순현금흐름:
$-26.38M
1주 성능:
+2.46%
1개월 성능:
+5.03%
6개월 성능:
-56.67%
1년 성능:
-77.75%
1일 변동 폭
$1.00
$1.08
1주일 범위
$1.00
$1.17
52주 변동 폭
$0.8401
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
1.04 | 16.30M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade
Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan
Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com
Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks
TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn
Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo
TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet
TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn
Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart
Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart
Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart
Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks
Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade
Tempest TherapeuticsEnters $50 Million Common Stock Purchase Agreement With Lincoln Park - TradingView
Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Tempest Therapeutics (TPST) Surges 13% as Biotech Momentum Builds Above Key SupportAnalyst Downgrade Signals - vinanet.vn
Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Tempest Therapeutics (TPST) Gains 3% as Biotech Stock Holds Ground Above $0.86 SupportFactor Momentum - vinanet.vn
Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Positive Gamma - dars.gov.et
Tempest Therapeutics (TPST) Shows Modest Uptick, Holding Above Key SupportPrice Target - vinanet.vn
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Tempest Therapeutics Adjourns Vote on Governance Changes - TipRanks
Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey
TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
TPST Q1 2026 Earnings: Wide EPS Miss Highlights Cash Burn ChallengesEarnings Growth Forecast - vinanet.vn
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks
Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com
Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative
Tempest Announces Development Collaboration with Senlang - GlobeNewswire
TPST Q1 2026 Earnings: Wide EPS Miss Highlights Ongoing Clinical-Stage LossesRevenue Per Share - vinanet.vn
Tempest Therapeutics (TPST) Inches Higher Near Resistance as Trading Remains SubduedDeath Cross - vinanet.vn
Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes - Stock Titan
William Drake Richey Net Worth (2026) - GuruFocus
Tempest advances next-generation in vivo CAR T pipeline - BioWorld News
Tempest Therapeutics (TPST) Slips 3.74% as Stock Tests Key Support ZonePut Call Ratio - vinanet.vn
Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com - Investing.com South Africa
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial - Quiver Quantitative
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, - GlobeNewswire
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):